Rishi Wadhwa, MD, of Shreveport, La.-based Specialists Hospital, completed the first implantation of Ventris Medical's Allocell AF allograft.

Orthobiologics company Kuros Biosciences has treated the first patient in a clinical trial comparing MagnetOs Putty to autograft for posterolateral spinal fusion.

The first two spinal surgery cases with TheraCell's TheraFuze DBF Fiber Bag were completed in Illinois and Texas.

Two professors from West Lafayette, Ind.-based Purdue University developed a shoulder implant that uses a patient's stem cells to help repair the rotator cuff.

From studies advancing spine treatment to new techniques in stem cell procedures, here are seven updates on biologics so far this year:

The global regenerative medicine market is projected to reach $39 million by 2030, up from $8.2 million in 2019, according to market research company P&S Intelligence.

Orthopedic biotechnology company Ortho Regenerative Technologies focused on developing soft tissue repair regenerative technology in 2020. For 2021, that development is expected to grow.

UC Davis Health in Sacramento, Calif., on March 1 announced the launch of the first FDA-approved human clinical trial using stem cells before birth to treat spina bifida, a defect that occurs when the spine and spinal cord do not form properly.

Patients injected with stem cells derived from their own bone marrow saw improvement in motor functions after spinal cord injuries, a study from New Haven, Conn.-based Yale University found.

Butte-based Montana Orthopedics' Anthony Russo, MD, became the first spine surgeon in the U.S. to implant Kore Fiber, a demineralized cortical fiber allograft.

DiscGenics, a biopharmaceutical company focused on regenerative therapies for spinal conditions, has completed construction on its 25,000-square-foot headquarters in Salt Lake City.

Orthobiologics company Bioventus launched its initial public offering, according to a Feb. 4 news release.

Orthobiologics company Bioventus is hoping to secure $100 million for its proposed stock offering, according to WRAL Tech Wire.

Richmond-based OrthoVirginia's Adam Crowl, MD, performed the first spinal fusion in clinic with the ViBone Moldable cell bone matrix, according to a Jan. 12 news release.

Peter Fields, MD, director of OrthoRegen in Santa Monica, Calif., is offering a stem cell therapy that combines four regenerative orthopedic procedures.

The global spinal biologics industry is projected to reach $2.3 billion by 2027, growing at a compound annual growth rate of 2.8 percent, according to ReportLinker.com.

Capital market company KICVentures Group has completed the acquisition of NanoFuse Biologics.

Health Canada has approved Zolgensma for the treatment of pediatric spinal muscular atrophy patients with three or less copies of the SMN2 gene, or infantile-onset SMA.

Eric Tobin has been announced as CEO of N2 Biomedical, a company providing coating and surface treatment for medical devices, according to a Dec. 2 press release.

A landmark clinical trial was announced in November when a $9 million grant was provided for the first human study using stem cells to treat a spinal disorder that occurs in babies in the womb.